Drug intelligence / Profile preview

HP-5120

Development stage: Unknown
Lead developer: Hisamitsu Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HP-5120 is a novel oral small molecule drug candidate currently under development by Hisamitsu Pharmaceutical. As of 2024, the compound is in early-phase clinical testing, specifically undergoing Phase 1 pharmacokinetic and safety evaluations in healthy Japanese adult volunteers. These studies, such as trial jRCT2031240331, include single ascending dose (SAD), sex-stratified single-dose, and 14-day multiple ascending dose (MAD) cohorts to characterize its safety profile and pharmacokinetic properties. While Hisamitsu is traditionally known for its transdermal drug delivery systems, HP-5120 represents an expansion of their pipeline into oral therapeutics. The specific biological target and primary therapeutic indication for HP-5120 have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on HP-5120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-5120.

Explore the full profile